Our News on Newswise

Belzutifan induced strong responses in patients with von Hippel-Lindau disease-associated kidney cancer

Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, achieved strong clinical activity in...
22-Nov-2021 2:55 PM EST Add to Favorites

Newswise: 6197afd17960e_101428_Yu_D.jpg

Antihistamines can influence immunotherapy response by enhancing T cell activation

Researchers discovered that antihistamines are associated with improved responses to immunotherapy. Their work revealed a role for the histamine receptor in suppressing T cell activation to block anti-tumor immune responses.
19-Nov-2021 9:25 AM EST Add to Favorites

MD Anderson Research Highlights for November 17, 2021

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include discovering a new...
17-Nov-2021 11:00 AM EST Add to Favorites

MD Anderson Research Highlights: SITC 2021 Special Edition

This special edition of MD Anderson's Research Highlights features presentations at the Society for Immunotherapy of Caner 36th Annual Meeting.
12-Nov-2021 8:00 AM EST Add to Favorites

Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases

Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by...
10-Nov-2021 8:00 AM EST Add to Favorites

MD Anderson Research Highlights for November 3, 2021

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include the...
3-Nov-2021 12:00 PM EDT Add to Favorites

Serial radiation therapy is safe and effective as alternative treatment to systemic therapy for kidney cancer

In a new single-arm study, researchers at The University of Texas MD Anderson Cancer Center reported that radiation therapy as monotherapy is a safe and effective noninvasive treatment for oligometastatic renal cell carcinoma (RCC). The findings...
27-Oct-2021 6:35 PM EDT Add to Favorites

MD Anderson Research Highlights: ASTRO 2021 Special Edition

This special edition features oral presentations by MD Anderson researchers at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting (Oct. 24-27) on novel therapeutic and diagnostic approaches, including partial breast irradiation,...
25-Oct-2021 6:15 PM EDT Add to Favorites


See All News

Our Experts on Newswise

Newswise: BenjaminSmith.jpg

Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT

Newswise: Liang_H_Bronto.jpg

Can Gender Play a Role in Determining Cancer Treatment Choices?

It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT

Newswise: ZhiminLu.jpg

MD Anderson Study Reveals New Insight Into Tumor Progression

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT

Newswise: Lee_M.jpg

Poor Survival Among Colorectal Cancer Patients Tied to Biomarker CSN6

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT

Newswise: 204929_Chhatwal_Jjpg.jpg

MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT

MD Anderson Joins CATCH Global Foundation to Boost Child Health, Prevent Cancer in Later Years

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST

MD Anderson Energy Balance Expert Available for Obesity, Cancer Stories

30-Oct-2013 8:10 PM EDT

MD Anderson Obesity and Cancer Expert Researches Food Addiction

30-Oct-2013 8:00 PM EDT

See All Experts

Our YouTube Videos

About

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 51 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospitals” survey. It has ranked as one of the nation’s top two hospitals for cancer care since the survey began in 1990 and has ranked first 16 times in the last 19 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Contacts

Clayton Boldt
Program Manager, Public Relations

crboldt@mdanderson.org

713-792-9518

Katrina Burton
Program Manager, Public Relations

kburton@mdanderson.org

713-792-8034

Shanley Chien
Program Manager, Public Relations

SHChien@mdanderson.org

713-563-4250

Lany Kimmons
Program Manager, Public Relations

rlkimmons@mdanderson.org

713-563-5801

Kelley Murfin
Senior Communications Specialist

kpmurfin@mdanderson.org

Meagan Raeke
Program Manager, Public Relations

meraeke@mdanderson.org

713-563-9340

Allison Schaffer
Program Manager, Public Relations

ASchaffer@mdanderson.org

713-745-1357

Twitter

close
0.7774